Are Peptides Legal in Washington? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Washington as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Washington attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Washington statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Washington has scheduled or banned on its own. The Washington Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Washington's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Washington at a glance

State controlled-substances law: Uniform Controlled Substances Act, RCW 69.50; Schedule III at RCW 69.50.208, supplemented by Pharmacy Quality Assurance Commission rule WAC 246-945-054 (app.leg.wa.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (RCW 69.50.208 and WAC 246-945-054 (Schedule III); see also WAC 246-853-220) (app.leg.wa.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Pharmacy Quality Assurance Commission's Statement on Compounding Semaglutide (approved 22 August 2024) says semaglutide may be compounded only when the drug is discontinued, on the FDA shortage list, or a specific patient's needs cannot be met by the commercial product; that salt forms are different active ingredients that do not meet FD&C Act requirements and may not be used; that any semaglutide base must be pharmaceutical grade (not research use only), with a valid certificate of analysis, from an FDA-registered and Washington-licensed source; and that non-compliance may bring disciplinary or enforcement action. A 28 March 2025 reminder extended the statement to all GLP-1s and noted the end of FDA enforcement discretion for tirzepatide and semaglutide compounding (2024-08-27) (content.govdelivery.com)
Medical board on peptide prescribing: The Washington Medical Commission's Statement of Compounding Semaglutide (22 August 2024) mirrors the pharmacy commission: compounding only under the shortage, discontinued or patient-specific exceptions; no salt form of semaglutide may be used because semaglutide is not on the FDA bulks list; the active ingredient must be pharmaceutical grade rather than research-use, with a certificate of analysis from FDA-registered and Washington-licensed sources. It also warns patients that these medications are legitimately available by prescription only. No commission statement on BPC-157 or peptide therapy generally was found (2024-08-22) (wmc.wa.gov)
GLP-1 by telehealth: Washington's Uniform Telehealth Act, chapter 18.134 RCW (effective 12 June 2024), holds a telehealth practitioner to the same professional standards as comparable in-person care, expressly including the standards and law on prescribing (RCW 18.134.040). There is no explicit in-person examination prerequisite for prescribing non-controlled drugs such as GLP-1s. The Medical Commission's telemedicine policy applies the same standard of care and ethics as in-person care. (app.leg.wa.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Washington, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Washington:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Washington. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Washington law adds

Washington's controlled-substances law (Uniform Controlled Substances Act, RCW 69.50; Schedule III at RCW 69.50.208, supplemented by Pharmacy Quality Assurance Commission rule WAC 246-945-054) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (app.leg.wa.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Washington's schedules or in a Washington-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Neither RCW 69.50.208 nor WAC 246-945-054 mentions growth hormone, somatropin or any peptide; both list anabolic steroids only. Separately, WAC 246-853-220 (a Board of Osteopathic Medicine rule) prohibits an osteopathic physician from prescribing anabolic steroids, growth hormones, testosterone, HCG or other hormones to enhance athletic ability or for nontherapeutic cosmetic purposes. That is a prescriber-conduct rule, not scheduling. (RCW 69.50.208 and WAC 246-945-054 (Schedule III); see also WAC 246-853-220) (app.leg.wa.gov)

Compounded semaglutide and tirzepatide

2024-08-27. The Pharmacy Quality Assurance Commission's Statement on Compounding Semaglutide (approved 22 August 2024) says semaglutide may be compounded only when the drug is discontinued, on the FDA shortage list, or a specific patient's needs cannot be met by the commercial product; that salt forms are different active ingredients that do not meet FD&C Act requirements and may not be used; that any semaglutide base must be pharmaceutical grade (not research use only), with a valid certificate of analysis, from an FDA-registered and Washington-licensed source; and that non-compliance may bring disciplinary or enforcement action. A 28 March 2025 reminder extended the statement to all GLP-1s and noted the end of FDA enforcement discretion for tirzepatide and semaglutide compounding. (content.govdelivery.com)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

2024-08-22. The Washington Medical Commission's Statement of Compounding Semaglutide (22 August 2024) mirrors the pharmacy commission: compounding only under the shortage, discontinued or patient-specific exceptions; no salt form of semaglutide may be used because semaglutide is not on the FDA bulks list; the active ingredient must be pharmaceutical grade rather than research-use, with a certificate of analysis from FDA-registered and Washington-licensed sources. It also warns patients that these medications are legitimately available by prescription only. No commission statement on BPC-157 or peptide therapy generally was found. (wmc.wa.gov)

Buying, possessing and using research peptides in Washington

No Washington provision specific to HGH or research peptides was found because neither is on the state schedules; knowing possession of a scheduled controlled substance without a valid prescription is a gross misdemeanor under RCW 69.50.4013, and otherwise the federal rules apply. (app.leg.wa.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Washington is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Washington's Uniform Telehealth Act, chapter 18.134 RCW (effective 12 June 2024), holds a telehealth practitioner to the same professional standards as comparable in-person care, expressly including the standards and law on prescribing (RCW 18.134.040). There is no explicit in-person examination prerequisite for prescribing non-controlled drugs such as GLP-1s. The Medical Commission's telemedicine policy applies the same standard of care and ethics as in-person care. (app.leg.wa.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Washington law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Washington

2025-03-13. The Pharmacy Quality Assurance Commission issued an immediate Limited Stop Service order against Aequita Pharmacy LLC of Kirkland, a compounder of GLP-1s including semaglutide and tirzepatide, barring it from compounding and dispensing in Washington for letting untrained staff perform sterile compounding, failing to supervise, not following sterile procedures and failing to implement an approved corrective action plan. (doh.wa.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. Washington's attorney general did not sign the February 2025 38-state letter to the FDA on GLP-1 sales, and no Washington AG action on peptides was found. Pending: HB 2613 (2026), establishing safety and regulatory requirements for compounded medications, was still in the House Health Care and Wellness committee on 28 September 2026; its GLP-1 or peptide content is unverified.

Frequently asked questions

Is BPC-157 legal in Washington?

Washington has not scheduled BPC-157, so possessing it is not a Washington offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Washington?

Washington's Uniform Telehealth Act, chapter 18.134 RCW (effective 12 June 2024), holds a telehealth practitioner to the same professional standards as comparable in-person care, expressly including the standards and law on prescribing (RCW 18.134.040). There is no explicit in-person examination prerequisite for prescribing non-controlled drugs such as GLP-1s. The Medical Commission's telemedicine policy applies the same standard of care and ethics as in-person care. The Washington Board of Pharmacy position on compounded versions: The Pharmacy Quality Assurance Commission's Statement on Compounding Semaglutide (approved 22 August 2024) says semaglutide may be compounded only when the drug is discontinued, on the FDA shortage list, or a specific patient's needs cannot be met by the commercial product; that salt forms are different active ingredients that do not meet FD&C Act requirements and may not be used; that any semaglutide base must be pharmaceutical grade (not research use only), with a valid certificate of analysis, from an FDA-registered and Washington-licensed source; and that non-compliance may bring disciplinary or enforcement action. A 28 March 2025 reminder extended the statement to all GLP-1s and noted the end of FDA enforcement discretion for tirzepatide and semaglutide compounding.

Is HGH legal in Washington?

Only with a valid prescription for an approved use. Washington does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Washington fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.